8-K: Braemar Hotels & Resorts Reports Mixed Q3, Pursues Sale

Braemar Hotels & Resorts Inc. reported a 15.1% increase in comparable Hotel EBITDA for Q3 2025, alongside a wider net loss, as the company actively pursues a strategic sale and refines its portfolio.

Summary

• Net loss attributable to common stockholders for Q3 2025 was $(8.2) million, or $(0.12) per diluted share, compared to $(1.4) million, or $(0.02) per diluted share, in Q3 2024.
• Adjusted Funds From Operations (AFFO) was $(0.19) per diluted share for Q3 2025, an improvement from $(0.24) per diluted share in Q3 2024.
• Adjusted EBITDAre for Q3 2025 was $16.4 million, down from $18.5 million in Q3 2024.
• Comparable Hotel EBITDA increased by 15.1% to $21.4 million for Q3 2025 compared to $18.6 million in Q3 2024.
• Comparable RevPAR for all hotels increased 1.4% to $257.45 in Q3 2025, with Comparable ADR up 4.7% to $400.72, while Comparable Occupancy decreased 3.2% to 64.25%.
• The company initiated a process for the sale of the company in August 2025, forming a Special Committee of independent directors.
• Successfully refinanced the mortgage loan for the Four Seasons Resort Scottsdale at Troon North, increasing the loan balance to $180 million at a lower interest rate (SOFR + 3.00% from SOFR + 3.75%).
• Closed on the sale of the Marriott Seattle Waterfront for $145 million, resulting in $50.8 million net proceeds after debt paydown and transaction costs.
• Entered into a definitive agreement to sell The Clancy in San Francisco for $115 million, with a $3.5 million non-refundable earnest money deposit received.
• Ended Q3 2025 with $116.3 million in cash and cash equivalents and $47.7 million in restricted cash.
• Net debt to gross assets was 43.2% at the end of Q3 2025.
• Capital expenditures during the quarter were $21.5 million.
• Redeemed approximately $18.5 million of non-traded preferred stock during the quarter, bringing the total redeemed to approximately $125 million.
• Declared a quarterly cash dividend of $0.05 per diluted common share for Q4 2025, payable January 15, 2026.

Sentiment

Score: 6

Explanation: The sentiment is mixed. Strong operational performance in comparable Hotel EBITDA and strategic asset sales are positive, but the widening net loss and declining occupancy are concerns. The initiation of a sale process adds uncertainty but also potential for shareholder value maximization.

Positives

• Comparable Hotel EBITDA increased significantly by 15.1% to $21.4 million, demonstrating strong operational performance at the hotel level.
• Comparable RevPAR grew by 1.4% and Comparable ADR increased by 4.7%, indicating pricing power and demand for the company's luxury properties.
• Adjusted FFO per diluted share improved to $(0.19) from $(0.24) in the prior year, showing a reduction in the net loss on an adjusted basis.
• Successful refinancing of the Four Seasons Resort Scottsdale loan at a lower interest rate (SOFR + 3.00% from SOFR + 3.75%) and increased loan amount ($180 million from $140 million) improves financial flexibility.
• Strategic portfolio refinement through the sale of Marriott Seattle Waterfront and the agreement to sell The Clancy, generating capital and focusing on maximizing shareholder value.
• No remaining debt maturities in 2025, providing near-term financial stability.
• Significant comparable Hotel EBITDA growth in several key resort properties, including The Ritz-Carlton Lake Tahoe (+380.98%), The Ritz-Carlton Reserve Dorado Beach (+796.00%), and Four Seasons Resort Scottsdale (+199.79%).

Negatives

• Net loss attributable to common stockholders widened significantly to $(8.2) million in Q3 2025 from $(1.4) million in Q3 2024.
• Adjusted EBITDAre decreased to $16.4 million from $18.5 million in the prior year quarter.
• Comparable Occupancy decreased by 3.2% to 64.25%, indicating lower utilization of hotel capacity.
• Cash and cash equivalents decreased to $116.3 million from $135.5 million at year-end 2024.
• Operating income decreased substantially to $29.8 million from $70.3 million in Q3 2024.
• Several properties experienced significant declines in comparable Hotel EBITDA, such as The Ritz-Carlton St. Thomas (-147.91%), Cameo Beverly Hills (-105.76%), and The Notary Hotel (-30.45%).
• The Capital Hilton Washington D.C. and Sofitel Chicago Magnificent Mile also saw declines in comparable Hotel EBITDA (-25.29% and -15.46% respectively).

Risks

• The sale process for the company has no deadline or definitive timetable, and there is no assurance that it will result in a sale.
• Forward-looking statements are subject to numerous assumptions and uncertainties, including the ability to repay, refinance, or restructure debt.
• Risks associated with the ability to effectuate the dividend policy, as the Board reviews it quarter-to-quarter and is not committed to future dividends.
• General volatility of the capital markets and the market price of common and preferred stock.
• Changes in the industry and markets in which the company operates, interest rates, or the general economy.
• The degree and nature of competition in the luxury hotel and resort sector.

Future Outlook

The company is initiating a process for its sale, with the Board of Directors forming a Special Committee to explore strategic alternatives to maximize shareholder value. There is no definitive timetable for the sale process, and no assurance it will result in a transaction. The company does not expect to provide updates unless a specific transaction is approved or disclosure is legally required. The Board will review its dividend policy on a quarter-to-quarter basis, with no commitment to future dividends.

Management Comments

• "I’m pleased with Braemar’s solid third quarter performance, highlighted by comparable RevPAR growth of approximately 1.4% and comparable total revenue growth of 3.9%."
• "Our property managers were able to generate strong flow-through on this revenue growth resulting in approximately 15% growth in comparable Hotel EBITDA."
• "Our resorts have resumed a more normalized growth trajectory, with the resort portfolio delivering solid comparable RevPAR growth of 5.5% over the prior year period."
• "To date, we have now redeemed approximately $125 million of our non-traded preferred stock and have no remaining debt maturities in 2025."
• "With the recent sale of the upper-upscale Marriott Seattle Waterfront and our announced agreement to sell The Clancy, we’re strategically refining our portfolio with a singular focus: maximizing shareholder value."
• "The divestiture of The Clancy represents another important step toward positioning the Company for a potential future sale that delivers the best possible outcome for our investors."

Industry Context

The luxury hotel and resort sector continues to show mixed performance. While Braemar's resort portfolio demonstrated solid comparable RevPAR growth of 5.5%, indicating resilience in high-end leisure travel, urban properties faced challenges. The overall industry is navigating fluctuating occupancy rates and rising operating costs, with a focus on strategic asset management and portfolio optimization. The company's move to sell non-core assets and explore a full company sale reflects a broader trend of consolidation and strategic repositioning within the hospitality REIT space, especially as interest rates and economic uncertainties persist.

Comparison to Industry Standards

• The 1.4% comparable RevPAR growth is modest compared to some luxury segments, but the 4.7% ADR growth suggests strong pricing power in its specific markets, aligning with a focus on high-value guests.
• The 8.1% capitalization rate on the Marriott Seattle Waterfront sale and 5.0% on The Clancy sale provide benchmarks for urban hotel valuations, reflecting market conditions and asset quality in specific geographies like Seattle and San Francisco.
• The refinancing of the Four Seasons Resort Scottsdale at SOFR + 3.00% indicates favorable lending terms for high-quality, luxury resort assets, potentially better than for less premium or urban properties in the current interest rate environment.
• The significant comparable Hotel EBITDA growth in properties like The Ritz-Carlton Lake Tahoe (+380.98%) and The Ritz-Carlton Reserve Dorado Beach (+796.00%) suggests strong recovery or exceptional performance in specific luxury resort destinations, potentially outperforming broader market averages for those segments, albeit from potentially lower bases in the prior year.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for value maximization through a company sale, but also uncertainty regarding the outcome and timing. Current dividend maintained at $0.05 per share.
• Employees: No direct impact mentioned, but a company sale could lead to future organizational changes.
• Creditors: Debt paydown from asset sales and successful refinancing of a major loan improve the company's debt profile and reduce immediate maturity risks.
• Customers (hotel guests): Continued operation and capital investment in properties (Capex of $21.5 million) suggest ongoing commitment to guest experience.

Next Steps

• Continue the process for the sale of the company, exploring strategic alternatives.
• Complete the definitive agreement to sell The Clancy in San Francisco.
• Board of Directors to review dividend policy on a quarter-to-quarter basis.
• Hold a conference call on November 5, 2025, to discuss Q3 2025 earnings.

Key Dates

Recommendation

While operational metrics like comparable Hotel EBITDA growth are positive and the company is actively pursuing strategic asset sales and a potential company sale to maximize shareholder value, the widening net loss and declining occupancy present headwinds. The uncertainty surrounding the company sale process, with no definitive timetable or assurance of completion, suggests a 'hold' position. Investors should monitor developments in the sale process and the company's ability to improve its bottom line and occupancy rates.

Keywords

Luxury Hotels, Resorts, REIT, Hotel Real Estate, Hospitality, SEC Filing, Earnings, RevPAR, EBITDA, Hotel Sales, Refinancing, Strategic Alternatives, Portfolio Management